check_circleStudy Completed

Diabetes Mellitus, Type 1

Bayer Identifier:

Trial_234

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

EU CT Number:

Not Available
Effect of 3 months of acarbose (BAY G 5421) therapy on the glycosylated haemoglobin content in the blood of children treated with insulin

Trial purpose

Please see attached Study Results Summary below.

Key Participants Requirements

Sex

N/A

Age

11 - 18 Years
  • -

  • -

Trial summary

Enrollment Goal
13
Trial Dates
October 1977 - September 1980
Phase
N/A
Could I Receive a placebo
N/A
Products
Acarbose (Precose/Glucobay, BAYG5421)
Accepts Healthy Volunteer
N/A

Trial design

Effect of 3 months of acarbose (BAY G 5421) therapy on the glycosylated haemoglobin content in the blood of children treated with insulin
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.